T-Advisor, through its tool Market Opportunities, has detected the company Amgen Inc., listed in Nasdaq, as an opportunity for investment.
These are the main figures about performances and volatility in the last years:
The technical analysis reveals also more data:
The chart shows the evolution i the last year:
Finally, the risk analysis is as follows:
Amgen Inc is an American biotechnological company specialized in the development of several kind of drugs, mainly for cancer diseases. It has subsidiaries and representatives offices in 35 countries around the worls. Total revenues in 2013 reached USD 18,676 million, a 8.17% more compared with the former year. Net income improved a 16,93%, till USD 5,081 million (USD 6.64 per share). The share increased the value a 133% in the last five years. The company has also a purchase strategy to grow, as it bought 7 laboratories in the last five years. Last purchase was Onyx Pharmaceuticals.